SELLAS Life Sciences Reaches 80th Event in Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia

Timeline

1. 28 Oct, 13:10 UTCFirst appeared on Google Trends
2. 28 Oct, 13:10 UTCPicked up on News

Top sources

• sls stockGoogle Trends
• Sellas Life Sciences: The Longer The Wait, The More Likely A REGAL Failure (NASDAQ:SLS)Seeking Alpha
• Sellas Life Sciences Reaches 80Th Event In Phase 3 Regal Trial Of Galinpepimut-S (Gps) In Acute Myeloid LeukemiaTradingView